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Epidermolytic hyperkeratosis is a rare autosomal domi-
nant inherited skin disorder caused by keratin 1 or ker-
atin 10 mutations. Keratins are major structural proteins
of the epidermis, and in keratinocytes committed to
terminal di¡erentiation the intermediate ¢laments are
composed of keratin 1 and keratin 10 heterodimers. The
majority of reported mutations (86.6%) are heterozy-
gous single point mutations and most of these are
located in the 1A and 2B regions of the highly con-
served keratin a-helical rod domain. We have studied
eight Scandinavian families with epidermolytic hyper-
keratosis and identi¢ed three point mutations, two co-
don deletions, two splice site mutations, and a complex
deletion/insertion. Two of the point mutations were in
the KRT1 gene (F191C and K177N) and the other was
in KRT10 (L453P). All three patients had associated pal-
moplantar keratoderma. The splice site mutations in
KRT1 both caused a large deletion removing 22 codons
(D176^197) from the 1A helical domain. Codon deletions
were found in KRT1 (D170^173) and in KRT10 (D161^162)
in two patients with a severe phenotype. A ¢nal patient
had a more complex mutation with a large deletion (442
bp) together with a large insertion (214 bp) of unknown
origin that caused deletion of exon 6 in KRT1. In con-
clusion, we have found eight novel keratin mutations
that cause epidermolytic hyperkeratosis with di¡ering
phenotypes. Even when a large part of keratin 1 (46
amino acids) is deleted, surprisingly mild phenotypes
can result, suggesting that genotypephenotype rela-
tionships in epidermolytic hyperkeratosis are complex
and do not solely depend on the type of mutation but
also depend on interactions between the behavior
of the mutant protein and the cellular environment.
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E
pidermolytic hyperkeratosis (EHK), clinically referred
to as bullous congenital ichthyosiform erythroderma,
is a rare autosomal dominant genodermatosis with a
prevalence of 1:100,000^1:300,000 (Bale et al, 1993).
Early symptoms include erythema, scaling, and blis-
tering, but blisters become less frequent with advancing age and
the skin becomes more hyperkeratotic, particularly in £exural
areas. The incidence and severity of palmoplantar keratoderma
(PPKD) is very variable and depends both on the gene mutated
and the speci¢c genotype.
Keratins are major structural proteins of the epidermis, skin ap-
pendages, and other epithelia. They are obligate heteropolymers,
requiring equimolar amounts of type I and type II proteins to
form functional ¢laments. Keratins are members of the inter-
mediate ¢lament multigene family and are expressed in a tissue-
and di¡erentiation-speci¢c manner. Ten major keratins are expres-
sed in human epidermis: K5 and K14 in the basal cells, K1 and
K10 in spinous and granular cells, K2e in upper spinous and gran-
ular cells, and K9 in suprabasal cells of palmoplantar epidermis.
Furthermore, some keratins (K6a, K6b, K16, and K17) are induci-
ble in interfollicular epidermis but constitutive in palmoplantar
epidermis and some skin appendages (Bowden, 1993).
Experiments with deletion constructs of K1, K5, K10, and K14
showed that removal of the 2B helical domain of a single keratin
protein would disrupt keratin ¢lament structure in cultured cells
and produce a skin disease phenotype in transgenic mice (Vassar
et al, 1991; Rothnagel et al, 1993; Bickenbach et al, 1996). At the
same time, the disease locus for epidermolysis bullosa simplex
(EBS) was linked to the keratin clusters on chromosomes 12q13
and 17q11 (Bonifas et al, 1992; McKenna et al, 1992). This linked
keratin mutations with two hereditary diseases of the epidermis,
EBS and EHK.
Keratin mutations have a dominant negative e¡ect and lead to
tono¢lament aggregation, cytoskeletal instability, and cellular
lysis in epidermal keratinocytes (Ishida-Yamamoto et al, 1992).
Thirty-nine causal keratin gene mutations, 20 in KRT1 and 19 in
KRT10, have been identi¢ed in patients with EHK. About half of
the cases are sporadic and therefore represent new mutations
(Rothnagel, 1996; Irvine and McLean, 1999). Most of them are
single heterozygous point mutations that cause single amino acid
substitutions, but rare dinucleotide alterations in KRT10 causing
substitution of two adjacent amino acids have been described ( Joh
et al, 1997; McLean et al, 1999). These mutations, as with those in
other keratin genes, are commonly located in either the H1, 1A, or
2B helical domains of the keratin protein, regions of highly con-
served amino acid sequence (Steinert and Roop, 1988). Patients
with associated PPKD generally have a defect in KRT1whereas
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those with no palmoplantar involvement have a defect in KRT10.
Some exceptions to this general rule have been reported, however
(Arin et al, 1999).
We have investigated eight patients from di¡erent families
with EHK. The clinical details and retinoid response have been
previously reported together with details of other EHK patients
(Virtanen et al, 2001). All eight patients had unique and novel
spontaneous keratin mutations in either KRT1 or KRT10 genes
and these were associated with a range of clinical phenotypes.
The most interesting mutation was a complex deletion/insertion
that caused the ¢rst reported deletion of a complete exon (KRT1
exon 6), thus removing 42 amino acids from the 2B helix of
the protein. Patients were informed of the study verbally and in
writing; the ethical committee approved the study (no. 97342).
MATERIALS ANDMETHODS
Patients Eight EHK patients from Sweden and Norway were
investigated. The clinical characteristics were variable and the clinical
diagnosis was con¢rmed by histopathology in all cases and by electron
microscopy in some patients (Anton-Lamprecht, 1994; 2000; Virtanen et al,
2001).
All patients except one (PaA: #2 inVirtanen et al, 2001) had no previous
family history of EHK. The situation for PaA (12 y old) is uncertain,
however, as he is of South American origin (adopted child with foster
parents) and no family history is available. This boy was observed from
age 2 and has a very severe form of EHK; large areas of his body have
thick hyperkeratotic skin with serious erosions and he has a very severe
PPKD (Fig 1a). Patient AS (#1; 12 y old) has a moderate phenotype
characterized by hyperkeratosis of the £exural areas, knees, elbows, and
Figure1. Variable phenotype among patients with EHK. Clinical details are shown for ¢ve of the investigated patients: (a) PaA; (b) VL; (c) EK;
(d) TA; (e) FJ.
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neck. The hyperkeratosis is more severe in the axilla and he has a di¡use,
mild PPKD. Patient VL (#7; 6 y old) has a di¡erent phenotype altogether
with more erythema and less hyperkeratosis than seen in the other cases
from Scandinavia. Large parts of the body are a¡ected, however, and he
has erosions on the buttocks and on the dorsum of the feet as well as a
moderate PPKD (Fig 1b).
Patient OH (#3, 16 y old) has a mild phenotype with thin
hyperkeratosis in £exural areas and crena ani as well as on the elbows and
knees. Large areas of his skin are essentially normal in appearance and he
has moderate PPKD. His symptoms were more severe during infancy
when the condition was characterized by erythema, blistering, and
ichthyosis. Patient EK (#4; 16 y old) was also born with general
erythema, erosions, and blisters, and his clinical appearance improved
with age. He has now moderate hyperkeratosis in £exural areas as well as
on the elbows and knees but mild hyperkeratosis on the neck and trunk.
He has super¢cial dry erosions on the buttocks and a mild di¡use PPKD
(Fig 1c).
Patient PA (#5; 30 y old) has thick hyperkeratotic skin on the elbows,
knees, in all £exural areas, neck, and on the face, with only a mild
hyperkeratosis on his torso. He has erythema and erosions that are
restricted to face, neck, hands, and feet, but his major problem is severe
PPKD. He was previously reported at 6 y of age (Gedde-Dahl, 1990).
Patient TA (#6; 41 y old) was born with a severe phenotype and was
published as EBS (K˛bner) at age 3, but later rediagnosed as EHK by
electron microscopy (Anton-Lamprecht, 1994; 2000). She now has
moderate to severe hyperkeratosis and erosions (blisters) mainly on the
feet, hands, knees, elbows, and £exural areas (Fig 1d) (Gedde-Dahl, 1971).
In addition, a mild erythema is found on the torso, legs, feet, and hands.
Apart from this, large parts of her skin look normal, although her PPKD is
severe. She has tried retinoid treatment several times but no improvement
was observed. Patient FJ (#8, 10 y old) has thick hyperkeratosis over large
parts of the body with no improvement with age. He has a generalized
erythema and erosions that are mostly located to the torso, arms, and feet
(Fig 1e). His palms and soles are completely normal.
Whole blood (2^10 ml) was taken from all patients and a shave biopsy
was taken from involved skin (1.5 cm2) of some patients for RNA
extraction. Blood samples were stored at ^201C and skin biopsies
at ^701C, until extracted. The local ethics committee at Uppsala
University and Oslo University approved the study.
Nucleic acid extraction and reverse transcription of RNA Genomic
DNA was extracted from 2.5 mL blood treated with ethylenediamine
tetraacetic acid using a Nucleon II kit (Scotlab, Glasgow, UK). Total
RNA was extracted from shave biopsies of involved skin (1.5 cm2) by
homogenization in TRIZOL reagent (Gibco BRL, Life Technologies,
Tby, Sweden). First-strand cDNA was synthesized from 3 mg of total
RNA in a 30 mL reaction mixture containing the oligo-dT primer,
nucleotide mix, bu¡er, and M-MLV reverse transcriptase (Gibco BRL).
After the reaction (371C for 60 min), 30 mL RNase free water was added
to make a ¢nal volume of 60 mL.
PCR and RT-PCR 100^200 ng of genomic DNA was added to the
mixture with 1Taq bu¡er, 0.2 mM of each dNTP, forward and reverse
primers (120 ng per mL), and 0.05 U of Taq polymerase (Promega,
Southampton, UK) in a total volume of 20 mL. The primers used are
listed in Table I. The PCRwas initiated with 7 min at 941C after which
the Taq polymerase enzyme was added (hot-start procedure). The reaction
was then continued for 30 cycles of 30 s at 941C, 50 s at 601C, and 3 min at
721C. The tubes were held at 721C for 15 min to complete fragment
elongation and the samples were then stored at 41C.
An aliquot of the reverse transcription reaction (1 mL) was used for the
RT-PCR in a ¢nal volume of 25 mL. This included 1PCR bu¡er II, 2.5
mM MgCl2, 0.2 mM of each dNTP, and 0.5 UAmpliTaq Gold polymerase
(Perkin-Elmer, Stockholm, Sweden). The primers were used at a ¢nal
concentration of 0.4 mM (Gibco BRL). The reaction was started at 941C
for 10 min followed by 30 cycles of 60 s at 941C, 75 s at 601C, and 90 s at
721C.
Cloning In order to investigate the e¡ect of the splice and deletion
mutations, fragments of cDNA (or gDNA) generated by RT-PCR (or
PCR) were cloned into a pT-Adv vector using AdvanTAge PCRCloning
Kit (Clontech, Palo Alto, CA). The speci¢c regions of KRT1 and KRT10
were ampli¢ed using the primers listed (Table I). Colonies were selected
on LB agar plates (Sigma-Aldrich Sweden, Stockholm, Sweden) with
X-gal (80 mg per ml), IPTG (47.5 mg per ml), and ampicillin (50 mg per
ml). Plasmid DNAwas prepared using a Jet Star 2.0 Plasmid Mini Kit 200
(Saveen, Malm ,˛ Sweden); the inserts were cut out with EcoRI and
analyzed on 1.5% agarose gels. Several clones with the correct insert size
were then sequenced.
Sequencing An aliquot (5 mL) of each PCRwas used for direct manual
sequencing by the dideoxy chain termination method (USB Sequenase
Version 2.0, Amersham International, Slough, UK). Primers were
dependent on the keratin gene and exon being screened: HK1p20R (50 -
aaacttgaggttcaaacc-30) for KRT1 (exon 1) and HK10p8R (50 -
ttcctctcattctctggc-30) for KRT10 (exon 6). Manual sequencing reactions
were analyzed on 6% polyacrylamide denaturing gels (Gibco-BRL, Life
Technologies, Paisley, UK), which were dried and exposed to X-ray ¢lm
(Kodak XAR-2). Automated sequencing was done using a Big Dye
Terminator kit and the samples were analyzed on an ABI Prism 377
DNA Sequencer (Perkin-Elmer Applied Biosystems, Foster City, CA).
PCRwere puri¢ed before sequencing with 1PEG solution (26% PEG
8000, 6.6 mM MgCl2, and 0.6 M NaAc, pH 5.2). The DNA was allowed
to precipitate for 10 min at room temperature followed by centrifugation
at 15000g for 30 min. The pellet was washed with 500 mL 70% ethanol,
air dried, and re-suspended in 5 mL sterile distilled H2O. The whole
volume of the PCR was used for sequencing gDNA from patients but
200^300 ng of plasmid DNA was used for sequencing the cloned DNA.
The primers used for automated sequencing are listed inTable II.
RESULTS
Variable phenotypes associated with nonconservative amino
acid substitutions in K1 or K10 Patient PaA has a very severe
form of EHK with severe PPKD (see Fig 1a) due a single
heterozygous point mutation (TTT to TGT) in exon 1 of KRT1
(data not shown). This mutation altered codon 191 (residue 11 of
the 1A helical domain) from phenylalanine to cysteine (F191C or
1A:F11C).The mutation deleted aTsp 509 I restriction enzyme site
from the normal allele generating a diagnostic fragment of 814 bp
from the mutant allele (Fig 2a).The phenotype of patient AS was
less severe and a moderate hyperkeratosis was localized to the
axilla, knees, and elbows together with mild PPKD. Sequencing
exon 1 of KRT1 (Fig 2b) identi¢ed a single heterozygous point
mutation (AAG to AAT) in codon 177, residue 33 of the H1
domain, changing lysine to asparagine (K177N or H1:K33N).
This created an EcoRI site in the mutant allele, which generated
two diagnostic fragments (610 bp and 214 bp) when cleaved (data
not shown). A third patient (VL) had a di¡erent phenotype
compared to the others. Hyperkeratosis was less prominent but
this patient had a generalized erythema and moderate PPKD.
Sequencing exon 6 of KRT10 (Fig 3a) identi¢ed a point
Table I. Primers used for PCR and RT-PCR
DNA Localization Forward primer Reverse primer
gDNA KRT1 exon 1 HK1pJ35 50 -aagtctctatgcttggggtagagg-30 HK1pJ46R 50 -atatctcctaggagaccattccac-30
cDNA KRT1 exon 1 HK1p22 50 -tggcatacaagaagtcac-30 K1 PCR R 50 -acactcacgttcggggcacattct-30
gDNA KRT1 exon 1 HK1p22 50 -tggcatacaagaagtcac-30 HK1p12R 50 -caccaatcccaagtggac-30
gDNA, cDNA KRT1 exon 5, 6, 7, and 8 K1 PCR F 50 -agtctcgacctggacagcatcatt-30 KI PCR R 50 -acactcacgttcggggcacattct-30
gDNA KRT10 exon 1 HK10p1 50 -aggagatggtggccttctctctgg-30 HK10p17R 50 -cacacttgctggatgaagattgcc-30
cDNA. KRT10 exon 1 K10 ex1 F 50 -ttcatggaagctatggaagtagca-30 K10 TM R 50 -gcagagctacctcattctcatacttc-30
gDNA KRT10 exon 6 HK10p14 50 -gccacaaaaaaatccgtttcaga-30 HK10p7R 50 -tgagaaagtgagattgcggttgcg-30
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mutation in codon 453 (CTA to CCA) that altered a leucine
residue to proline (L453P) in the 2B helical domain of the
protein (2B:L114P). The mutation resulted in loss of a Bfa I site,
giving rise to a diagnostic fragment of 399 bp (Fig 3b).
Splice site mutations in KRT1 lead to an in-frame deletion
of 22 amino acids Patients OH and EK had a similar but not
identical mild EHK phenotype with mild to moderate PPKD.
Manual sequencing of genomic DNA from these two patients
revealed a point mutation in the 50 splice site of intron 1 (KRT1).
The alteration was di¡erent in the two patients examined,
however: OH had a single heterozygous base change (GT to AT)
whereas the alteration in patient EK was at the same splice site
but a di¡erent base change, GT to CT (Fig 4a). In both cases a
restriction enzyme site for Hph 1was lost from the mutant allele,
which yielded a diagnostic 200 bp fragment (data not shown).
To examine the consequences of the splice site mutation,
mRNA encoding this region was ampli¢ed from each patient
by RT-PCR and the cDNA fragments were cloned. In both
cases, ampli¢cation of exons 1^8 of KRT1 cDNA gave two
fragments, 1061 bp and 995 bp (Fig 4b). In contrast, PCR
ampli¢cation of cDNA from normal skin and from other EHK
patients gave only the larger 1061 bp fragment. Interestingly, not
only was the mutant allele under-represented in both patients but
the level of under-representation also di¡ered between them.The
expression of the mutant allele was estimated to be higher for
patient EK compared to patient OH (Fig 4b). Sequencing of the
mutant KRT1 allele showed that a 66 nucleotide in-frame
deletion occurred that resulted in removal of 22 amino acids
from the end of the H1 and beginning of the 1A domains (Fig
5a). This can be explained by use of a cryptic splice site
(AAGGTGAAG) site, 66 bp upstream of the normal intron 1
splice site (AAGGTGAGT) resulting in loss of codons 176^197
(Fig 5b). The splice site sequence involved was found to be
invariant by analysis with Hph I in 50 samples (100 alleles) of
normal genomic DNA.
A 12 bp in-frame deletion in KRT1 causes a severe pheno-
type Patient PA has a phenotype with severe PPKD. The
gDNA encoding exon 1 of KRT1 gave sequence data typical for
a deletion or insertion mutation (data not shown). PCR
ampli¢cation of patient gDNA over this region produced two
short fragments (199 bp and 187 bp) with a 12 bp di¡erence
(Fig 6a) rather than the single fragment obtained with normal
gDNA. These two fragments were cloned and the individual
alleles were sequenced. The sequence showed an in-frame
deletion of 12 bp at the end of the H1 domain in KRT1 (Fig
6b). This deletion removes four conserved amino acids
(D170173) at positions 26^29 in the H1 domain of K1. This
deletion abolishes a restriction enzyme site for Dde I and gives a
diagnostic fragment of 732 bp (data not shown).
A large deletion and insertion mutation abolishes exon 6 in
KRT1 Patient TA has a moderate phenotype with an associated
severe PPKD. PCR ampli¢cation of gDNA over exons 5^8
of KRT1 gave two DNA fragments (1803 bp and 1575 bp)
Table II. Primers used for automatic sequencing
DNA Region Primer sequences
gDNA KRT1 exon 1 HK1p12R 50 -caccaatcccaagtggac-30
cDNA, recombinant cDNA KRT1 exon 1 HK1p22 50 -tggcatacaagaagtcac-30
Recombinant gDNA KRT1 exon 1 M13 reverse 50 -aacagctatgaccatg-30
Recombinant gDNA KRT1 exon 5, 6, and 7 K1 ex7 R 50 -atccttgagggcattctcgc-30
cDNA, recombinant cDNA KRT1 exon 5, 6, and 7 K1 PCR F 50 -agtctcgacctggacagcatcatt-30
gDNA KRT10 exon 1 HK10p1 50 -aggagatggtggccttctctctgg-30
cDNA, recombinant cDNA KRT10 exon 1 K10 ex1 F 50 -ttcatggaagctatggaagtagca-30
Figure 2. Novel heterozygous single point mutations in KRT1 cause
EHK with variable phenotype. (a) Restriction fragment length poly-
morphism analysis of the F191C mutation in K1 for patient PaA. The mu-
tant allele gives rise to an 814 bp fragment due to the loss of the Tsp 509 I
site. (b) Patient AS has a point mutation in codon 177, changing lysine to an
asparagine residue (K177N). Automatic sequencing of exon 1 in KRT1
shows the reverse strand. M is a molecular size marker.
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compared to only one fragment (1803 bp) in normal controls
(data not shown). The two fragments were cloned and
sequencing of the mutant allele showed a 442 bp deletion
(nucleotides 4442^4883 inclusive) together with a 214 bp
insertion from elsewhere in the genome (Fig 7a). Database
searches identi¢ed no speci¢c matches with the inserted DNA,
which appears to be a common repetitive sequence found
throughout the genome. The KRT1 gene deletion included the
end of intron 5, all of exon 6, and almost 50% of intron 6. RT-
PCR of patient mRNA encoding the 2B region also gave two
fragments. These were cloned and sequencing showed that the
whole of exon 6, which encodes 42 amino acids (codons
377^418), was absent from the mutant allele (Fig 7b).
A 6 bp in-frame deletion in KRT10 causes a severe pheno-
type without PPKD Patient FJ has a severe form of EHK but
no associated PPKD. Sequencing of gDNA and cDNA encoding
exon 1 of KRT10 gave an unreadable sequence typical of deletion
or insertion mutations (data not shown). PCR-ampli¢ed cDNA
encoding exon 1 was cloned and the two alleles were sequenced
separately. A 6 bp in-frame deletion was found in the mutant
allele that removes two codons (161^162), leucine and aspartic
acid at positions 15 and 16 in the 1A domain of KRT10 (Fig 8).
No restriction fragment length polymorphisms were found for
this mutation.
The other hotspot regions of both KRT1 and KRT10 were
sequenced in all patients and no alterations other than those
Figure 3. A novel heterozygous single point mu-
tation in KRT10 causes EHKwith PPKD. (a) Man-
ual sequencing of KRT10 (exon 6) in patient VL
showed a point mutation in codon 453 changing a leu-
cine residue to proline (L453P), residue 114 of the 2B
helical domain. (b) Restriction fragment length poly-
morphism analysis of the L453P mutation in KRT10
using the restriction enzyme Bfa I. The mutant allele
has a diagnostic 399 bp fragment due to loss of the
Bfa I site.
Figure 4. Splice site mutations in KRT1 causing a mild EHK. (a)
Patients OH and EK have a single heterozygous point mutation in the 50
splice site of intron 1 in KRT1. Manual sequencing of genomic DNA from
both patients and normal control (C) are shown. (b) PCR fragments cover-
ing exons 1^8 ampli¢ed from patients OH and EK yield two fragments
(1061 bp and 995 bp) compared to the single fragment (1061 bp) from nor-
mal control cDNA. PCR fragments were separated on a 1.5% agarose gel.
Figure 5. Cloning of the mutant allele in KRT1 revealed a 22 amino
acid deletion (H1þ1A). (a) The mutant allele from patients OH and EK
uses a cryptic splice site located 66 nucleotides upstream of the normal
splice site. Automatic sequencing of the normal and mutant allele of
KRT1 from EK is shown. (b) Schematic showing how the two di¡erent
alleles (normal and mutant) are spliced in patients OH and EK.
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described above were found. Restriction fragment length
polymorphism analysis was done on a minimum of 50 normal
genomic DNA samples (100 alleles) showing that none of these
alterations represented a polymorphism normally present in the
human population (data not shown).
DISCUSSION
As the number of keratin gene mutations identi¢ed increases, the
simple genotypephenotype relationships that were ¢rst pro-
posed have become inadequate. It is now clear that a much more
complex situation exists and, although some generalizations can
be made, these do not seem to be surviving the test of time. Clin-
ical heterogeneity in EHK has been classi¢ed into six subtypes
Figure 6. A 12 bp in-frame deletion in the H1 domain of KRT1
causes severe EHK. (a) PCR of exon 1 in KRT1 for patient PA gave rise
to two fragments (199 bp and 187 bp). The fragments were separated on a
3% NuSieve plus 1% agarose gel. (b) The mutant allele of KRT1 from
patient PA has a 12 bp deletion that removes residues 170^173 in the K1
protein.
Figure 7. An insertion together with a deletion removes the whole
of exon 6 a¡ecting the 2B domain of K1. (a) A schematic showing the
442 bp deletion and the 214 bp insertion in KRT1. (b) Sequence analysis of
exons 5, 6, and 7 of KRT1 cDNA. In the mutant allele, the sequence of
exon 5 is followed by exon 7.
Figure 8. A 6 bp deletion in the 1A domain of KRT10 causes a
severe EHK phenotype. Automatic sequencing of the 1A domain of
KRT10 (normal and mutant alleles). A 6 bp deletion removes residues 161
and 162 (leucine and aspartic acid) in the K10 protein.
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(DiGiovanna and Bale, 1994). KRT1 mutations have been asso-
ciated with EHK cases that also have a PPKD phenotype whereas
KRT10 mutations are usually associated with EHK cases that do
not. This association with PPKD appears to be true for KRT1
mutations, but recently a KRT10 mutation has been identi¢ed in
a patient with a very severe phenotype that includes PPKD (Arin
et al, 1999).We now describe another KRT10mutation that alters a
residue in the 2B helical domain (L453P or 2B:L114P) in a patient
who has a very severe phenotype and PPKD. Interestingly, the
same mutation in the adjacent codon (L452P or 2B:L113P) pub-
lished recently (McLean et al, 1999) does not have associated
PPKD.
The other two heterozygous point mutations were in KRT1
and they have di¡erent clinical phenotypes. The most severely
a¡ected patient had a nonconservative substitution in the 1A
domain (F191C or 1A:F11C). This residue when mutated in K5
(F179S) causes the most severe EBS phenotype (Stephens et al,
1997) and a similar alteration in K6a (F174S) causes a severe form
of pachyonychia congenita type I (Smith et al, 1999). This residue
must therefore be structurally important for keratin assembly and
stability and any change will cause severe perturbation to the ¢la-
ment system and give rise to a severe clinical phenotype.
The other KRT1 mutation is another nonconservative altera-
tion that a¡ects the H1 domain of the protein. Altering codon
177 from lysine to asparagine (K177N or H1:K33N) was asso-
ciated with moderate disease in £exural regions including the ax-
illa, elbow, knee, and neck but very mild disease on the trunk
and mild PPKD. This mutation site has not previously been re-
ported in any other keratin gene as causing disease. Our own
data,1 however, show that the adjacent residue (S178) causes a si-
milar but more severe phenotype when mutated to proline
(S178P or H1:S34P). Furthermore, the mutation K177N replaces
a positively charged amino acid with a neutral residue, which
would a¡ect the overall charge in a region of the protein that is
important for dimer formation.
Surprisingly, the large deletion of 22 amino acids, which re-
sulted from a splice site mutation in the KRT1 gene, gave rise to
a mild EHK phenotype. Even more surprising was the fact that
the phenotype of the two patients who had the same alteration at
the protein level also di¡ered. The use of a cryptic splice site in
exon 1 upstream of the authentic site deleted 66 nucleotides.
These encoded the last ¢ve residues of the H1 domain (including
K177 and S178) and the ¢rst 17 amino acids of the 1A domain (in-
cluding L187, N188, F191, and I195), all of which are known to
cause moderate to severe EHKwith PPKD (Yang et al, 1994; Arin
et al, 1999). Therefore, this large deletion would be expected to
cause a severe phenotype, but it does not. One possible reason
for this is that the mutant allele is under-represented and that
there is a relative lack of mutant protein production. As the
EHK phenotype is generated by a dominant negative e¡ect of
the mutant protein, then levels must be equal to those of the nor-
mal protein. When we examined the mRNA levels of the two
alleles by RT-PCR, however, we found that the mutant allele
was under-represented. Furthermore, the mutant allele in the pa-
tient with the milder phenotype was under-represented to a
greater extent. This would lead to lower levels of the mutant pro-
tein in these patients and therefore less of a dominant negative
e¡ect. A similar situation has recently been described for an iden-
tical mutation in the KRT5 gene (Rugg et al, 1999). This also af-
fected the donor splice site of intron 1 and this resulted in the use
of an upstream cryptic splice site having an identical e¡ect on the
K5 protein, removing 22 amino acids from the H1 and 1A do-
mains. In this case, the mutant allele was also under-represented
and gave rise to a milder than expected phenotype. Another pos-
sibility, however, is that such a large deletion in the H1 and 1A
domains of K1 would interfere with dimer formation and lead
to proteolysis of the monomer polypeptide chains.
The 12 bp deletion mutation in exon 1 of KRT1 encodes a
highly conserved domain that is required for ¢lament alignment.
Two of the deleted residues are hydrophobic whereas the other
two are negatively charged amino acids. Such a large deletion in
the protein sequence would probably interfere with ¢lament
alignment, have a dramatic e¡ect on keratin intermediate ¢la-
ment stability, and lead to a severe clinical phenotype.
Another deletion mutation removed two adjacent codons (L161
and D162) in the 1A helical domain of KRT10. A dominant nega-
tive point mutation in one of these KRT10 codons (L161S) has
previously been reported in a family with a severe EHK pheno-
type including PPKD (Rothnagel et al, 1992). Removal of this
and the adjacent codon in this deletion, however, does not cause
an associated PPKD and the patient in our study has normal
palms and soles.
The last patient has a complex KRT1mutation with a large de-
letion (442 bp from intron 5 to intron 6 including the whole of
exon 6) together with an associated insertion of 214 bp from else-
where in the genome. Exon deletion mutations have not been
reported in any keratin before and mutations in this region of
K1 have not been previously reported. Deleting exon 6 removes
42 amino acids from the beginning of the 2B helical domain
(2B:5^46) distal from the helix termination peptide. Although
this is a very large deletion, it appears to have little dominant
negative e¡ect and the phenotype observed is moderate. The rea-
son for this could be due to the mutant allele being unstable and
therefore under-represented as for the two splice site mutations.
Although this could be investigated by western blotting of pro-
tein extracts from keratinocytes obtained from these patients with
a K1 antibody, this was not done at the time, and it is not possible
to do in retrospect for practical and ethical reasons. One possible
mechanism that might explain this mutation is unequal crossover,
which generally occurs within a repeat but can occasionally hap-
pen in regions with little homology.
We conclude from examining these eight patients from the
same geographic region that genotypephenotype relationships
in patients with EHK are very complex. EHK is generally more
severe in early childhood so the phenotype also depends on the
age of the patient. The genotypephenotype relationships de-
pend not only on which keratin is mutated but also on the posi-
tion of the mutation within the gene, on the functional
signi¢cance of the actual amino acid substitution, and on the le-
vel of mutant allele expression. This has also been found to occur
in transgenic mice, where gene dosage of an introduced mutation
has a dramatic e¡ect on the eventual phenotype (Bickenbach et al,
1996). There are also keratin mutations where the genetic back-
ground appears to modulate the phenotype. Exploitation of these
facts may lead to alternative ways of attaining gene therapy in
such patients as the route of gene ablation and replacement in epi-
dermal stem cells still appears a future dream.
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